Dr Catherine Owczarek is the Director of the Recombinant Protein Expression Group (CSL Limited) located at the Bio21 Institute in Melbourne, Australia. After gaining a PhD at the John Curtin School of Medical Research, Canberra, she completed her post-doctoral studies at the Sir William Dunn School of Pathology in Oxford, the Walter and Eliza Hall Institute in Melbourne and then was a Senior Research Fellow at the Monash Institute of Medical Research in Melbourne. Since joining CSL Limited Catherine has led the CSL Research Group’s efforts in the successful development of a program to produce mammalian-derived recombinant proteins using transient gene expression systems. She is involved in a range of CSL’s early phase drug discovery campaigns for the prevention and/or treatment of human diseases. A significant achievement has been the discovery and development of the human anti-beta common antagonist trabikibart/CSL311 that is now in first-in-human clinical trials and will be used for the treatment of severe asthma.